Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

PHASE4CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

October 29, 2015

Primary Completion Date

June 2, 2017

Study Completion Date

June 2, 2017

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

empagliflozin 10mg

DRUG

empagliflozin 25 mg

DRUG

Placebo

For blinding purposes

Trial Locations (16)

819-0168

Kunisaki Makoto Clinic, Fukuoka, Fukuoka

963-8851

Seino I.M. Clinic, Fukushima, I.M., Fukushima, Koriyama

721-0927

Nippon Kokan Fukuyama Hospital, Hiroshima, Fukuyama

311-0113

Nakakinen Clinic, Ibaraki, Naka

214-0014

Kubota Clinic, Kanagawa, Kawasaki

242-0004

Medical Corporation Yuga Higashirinkan Kaneshiro Diabetes Clinic, Kanagawa, Yamato-shi

232-0064

Yokohama Minoru Clinic, Kanagawa, Yokohama

510-0829

Yokkaichi Diabetes Clinic, Mie, Yokkaichi

582-0005

Shiraiwa Medical Clinic, Osaka, Kashiwara-shi

530-0001

AMC Nishi-umeda Clinic, Osaka, Osaka-shi

565-0853

OCROM Clinic, Osaka, Suita

103-0027

Fukuwa Clinic, Tokyo, Chuo-ku

Tokyo-Eki Center-building Clinic, Tokyo, Chuo-ku

192-0918

Minamino Heart Clinic, Tokyo, Hachioji

160-0022

ToCROM Clinic, Tokyo, Shinjuku-ku

169-0073

Shinjuku Research Park Clinic, Tokyo, Shinjuku-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02589626 - Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA | Biotech Hunter | Biotech Hunter